Breast Cancer Coverage From Every Angle
Advertisement
Advertisement

Meredith M. Regan, ScD, on Early Breast Cancer: Update on the TEXT and SOFT Trials

Posted: Thursday, December 7, 2017

Meredith M. Regan, ScD, of the Dana-Farber Cancer Institute, discusses study findings comparing adjuvant aromatase inhibitor exemestane plus ovarian function suppression (OFS) vs tamoxifen plus OFS in premenopausal women with HR+ early breast cancer.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.